SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
Abstract Introduction Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors (n = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (p-value = 0.11). Conclusion The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process.
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
2022
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000100013 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2531-13792022000100013 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2531-137920220001000132022-03-16SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibilityCrocchiolo,RobertoAlfarano,FrancescoVolpato,ElisabettaPugliano,MariateresaCuppari,IreneMazza,Anna MariaBellio,LauraFanti,DianaVismara,ChiaraScaglione,FrancescoSacchi,NicolettaPollichieni,SimonaMele,LiaDiral,ElisaGrillo,GiovanniRossini,Silvano Sars-cov-2 Hematopoietic stem cells Donors Eligibility Screening Abstract Introduction Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors (n = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (p-value = 0.11). Conclusion The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.44 n.1 20222022-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000100013en10.1016/j.htct.2021.09.017 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Crocchiolo,Roberto Alfarano,Francesco Volpato,Elisabetta Pugliano,Mariateresa Cuppari,Irene Mazza,Anna Maria Bellio,Laura Fanti,Diana Vismara,Chiara Scaglione,Francesco Sacchi,Nicoletta Pollichieni,Simona Mele,Lia Diral,Elisa Grillo,Giovanni Rossini,Silvano |
spellingShingle |
Crocchiolo,Roberto Alfarano,Francesco Volpato,Elisabetta Pugliano,Mariateresa Cuppari,Irene Mazza,Anna Maria Bellio,Laura Fanti,Diana Vismara,Chiara Scaglione,Francesco Sacchi,Nicoletta Pollichieni,Simona Mele,Lia Diral,Elisa Grillo,Giovanni Rossini,Silvano SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility |
author_facet |
Crocchiolo,Roberto Alfarano,Francesco Volpato,Elisabetta Pugliano,Mariateresa Cuppari,Irene Mazza,Anna Maria Bellio,Laura Fanti,Diana Vismara,Chiara Scaglione,Francesco Sacchi,Nicoletta Pollichieni,Simona Mele,Lia Diral,Elisa Grillo,Giovanni Rossini,Silvano |
author_sort |
Crocchiolo,Roberto |
title |
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility |
title_short |
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility |
title_full |
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility |
title_fullStr |
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility |
title_full_unstemmed |
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility |
title_sort |
sars-cov-2 screening in allogeneic hematopoietic stem cell donors: implications for the evaluation process and eligibility |
description |
Abstract Introduction Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility. Methods We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process. Results A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors (n = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (p-value = 0.11). Conclusion The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process. |
publisher |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) |
publishDate |
2022 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000100013 |
work_keys_str_mv |
AT crocchioloroberto sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT alfaranofrancesco sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT volpatoelisabetta sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT puglianomariateresa sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT cuppariirene sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT mazzaannamaria sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT belliolaura sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT fantidiana sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT vismarachiara sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT scaglionefrancesco sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT sacchinicoletta sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT pollichienisimona sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT melelia sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT diralelisa sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT grillogiovanni sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility AT rossinisilvano sarscov2screeninginallogeneichematopoieticstemcelldonorsimplicationsfortheevaluationprocessandeligibility |
_version_ |
1756442080101531648 |